Custom DNA oligos
Ended Awarded
- Contract number
- 75N91022F00001
- Awardee
-
Integrated DNA Technologies, Inc. UEI P55FTN1UMYZ1 Part of Danaher Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,604
Award facts
- Contract value 100% obligated
- $14,603.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325199 All Other Basic Organic Chemical Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Coralville, IA 52241, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a $14,603.98 firm fixed price Blanket Purchase Agreement (BPA) call to Integrated DNA Technologies, Inc. (IDT) on March 23, 2022, for custom DNA oligonucleotides. The contract was performed in Coralville, Iowa, with an ultimate completion date of August 31, 2022. No set-aside designation was utilized for this procurement, indicating IDT competed in an open market competition. IDT, a specialized manufacturer of custom nucleic acid products including DNA and RNA oligonucleotides, gene fragments, and sequencing reagents, leveraged its established position as a key federal supplier of molecular biology products to support the National Cancer Institute's research initiatives.
As a subsidiary of Danaher Corporation, IDT has developed substantial federal contracting capabilities across multiple agencies including the National Institutes of Health, Centers for Disease Control and Prevention, and the Department of Defense. The company maintains several significant Indefinite Delivery Vehicles, including a $5 million BPA with the Defense Health Agency and a $10 million BPA with the National Institute of Neurological Disorders and Stroke, which enable efficient delivery of custom oligonucleotides and specialized molecular biology reagents. This particular National Cancer Institute award represents a task order execution under IDT's established contracting relationships, supporting critical biomedical research and cancer-related scientific investigations that align with the institute's mission in genomic and molecular research.
Quick answers
Who was awarded contract 75N91022F00001?
75N91022F00001 was awarded to Integrated DNA Technologies, Inc. by National Cancer Institute (National Institutes of Health) on March 23, 2022.
How much is contract 75N91022F00001 worth?
The government has obligated $14,604 on 75N91022F00001.
Is contract 75N91022F00001 an order under another contract?
Yes. 75N91022F00001 is a BPA call under HHSN263201500214B, a blanket purchase agreement.
Was contract 75N91022F00001 competed?
The extent of competition for 75N91022F00001 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award